Monoclonal antibodies targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis are approved as both first- and second-line treatments for advanced NSCLC [9]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.